SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: ggamer who wrote (338)10/5/2007 3:35:19 PM
From: Keith FeralRead Replies (1) | Respond to of 418
 
I was looking at the Avastin protocols to see how they compare to the Cofactor + Avastin protocols for the phase 3. The phase 2 trial tested Cofactor in monotherapy to determine safety and efficacy. They received approval to do the phase 3 in combination therapy with Avastin.

As I look at the Avastin trials, I can see why bolus Cofactor would be a good fit.



To: ggamer who wrote (338)10/5/2007 5:21:06 PM
From: Keith FeralRead Replies (1) | Respond to of 418
 
Here are the other methods of delivery.

Cofactor + 5FU 60 mg Cofactor bolus + 450 mg 5FU
Repeat weekly for 6 weeks every 7 weeks

Cofactor + 5FU DeGramont 60 mg Cofactor and 500 mg 5FU
600 mg 5FU continuous
Day 2
60 mg Cofactor and 500 mg 5FU
600 mg 5FU

LV + 5FU DeGramont 500 mg LV + 500 mg 5FU
600 mg LV continuous

Repeat same on Day 2.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News